DSM-Firmenich stock follows raised 2026 sales outlook after Q3

On November 4, 2026, dsm-firmenich raised its full-year like-for-like sales growth outlook to around 5 percent from a previous range of 2 to 4 percent. The company said third-quarter growth was volume-led and that conditions entering the final quarter remained supportive, according to its Q3 2026 trading update.

Volume Growth Supports Higher Target

Continuing operations generated third-quarter sales of 2.368 billion euros, compared with 2.238 billion euros a year earlier. Like-for-like growth was 5 percent, supported by high win rates on customer briefs and solid performance across regional and local accounts.

Adjusted EBITDA rose 8 percent on a like-for-like basis to 482 million euros. The adjusted EBITDA margin reached 20.4 percent, despite an 80-basis-point negative foreign-exchange effect against the prior-year quarter. Cost savings, restructuring measures and pricing actions remain part of the response to cost inflation.

Targets Remain Unchanged

For the full year, dsm-firmenich continues to target an adjusted EBITDA margin of around 20 percent and cash conversion of 11 to 12 percent, measured as adjusted gross operating free cash flow to sales. Management said the 2026-2028 action plan was on track and pointed to a healthy innovation pipeline and continued sales growth.

DSM-Firmenich stock traded at 109.50 euros on Lang & Schwarz at 17:41 CET on Friday, November 6, 2026.

Investors can follow the real-time quote of DSM-Firmenich stock for the latest market indication.

European equity sentiment remains the broader backdrop for the Swiss group; see current SMI market coverage.

More news and analyses on DSM-Firmenich stock.